fenofibrate has been researched along with Ventricular Dysfunction, Left in 8 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fenofibrate treatment blunted reduction in left ventricular ejection fraction, reduced cardiac hypertrophy, and attenuated clinical signs of heart failure." | 5.34 | The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. ( Brigadeau, F; Duriez, P; Fruchart, JC; Gelé, P; Lacroix, D; Marquié, C; Martin-Nizard, F; Staels, B; Torpier, G; Wibaux, M, 2007) |
| "Fenofibrate is a peroxisome proliferator-associated receptor alpha agonist (PPARα) used clinically for the management of dyslipidemia and is a myocardial fatty acid oxidation stimulator." | 1.39 | Fenofibrate reduces cardiac remodeling and improves cardiac function in a rat model of severe left ventricle volume overload. ( Arsenault, M; Couet, J; Dhahri, W; Drolet, MC; Roussel, É, 2013) |
| "Fenofibrate pretreatment (fenofibrate + LPS group) did not alter signs of endotoxemia but prevented reductions in both cardiac contractility and myofilament Ca2+ sensitivity." | 1.34 | Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats. ( Bordet, R; Brisson, H; Callebert, J; Gelé, P; Jozefowicz, E; Lebuffe, G; Mebazaa, A; Rozenberg, S; Tavernier, B; Vallet, B, 2007) |
| "Cardiotoxicity is a treatment-limiting side effect of the anticancer drug doxorubicin (DOX)." | 1.34 | Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity. ( Duan, Z; Furuhashi, K; Ichihara, G; Ichihara, S; Kawai, Y; Osawa, T; Yamada, Y, 2007) |
| "Fenofibrate treatment blunted reduction in left ventricular ejection fraction, reduced cardiac hypertrophy, and attenuated clinical signs of heart failure." | 1.34 | The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. ( Brigadeau, F; Duriez, P; Fruchart, JC; Gelé, P; Lacroix, D; Marquié, C; Martin-Nizard, F; Staels, B; Torpier, G; Wibaux, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhahri, W | 1 |
| Couet, J | 1 |
| Roussel, É | 1 |
| Drolet, MC | 1 |
| Arsenault, M | 1 |
| Morgan, EE | 1 |
| Rennison, JH | 1 |
| Young, ME | 1 |
| McElfresh, TA | 1 |
| Kung, TA | 1 |
| Tserng, KY | 1 |
| Hoit, BD | 1 |
| Stanley, WC | 1 |
| Chandler, MP | 1 |
| Jozefowicz, E | 1 |
| Brisson, H | 1 |
| Rozenberg, S | 1 |
| Mebazaa, A | 1 |
| Gelé, P | 2 |
| Callebert, J | 1 |
| Lebuffe, G | 1 |
| Vallet, B | 1 |
| Bordet, R | 1 |
| Tavernier, B | 1 |
| Fernandes, CJ | 1 |
| Ichihara, S | 1 |
| Yamada, Y | 1 |
| Kawai, Y | 1 |
| Osawa, T | 1 |
| Furuhashi, K | 1 |
| Duan, Z | 1 |
| Ichihara, G | 1 |
| Brigadeau, F | 1 |
| Wibaux, M | 1 |
| Marquié, C | 1 |
| Martin-Nizard, F | 1 |
| Torpier, G | 1 |
| Fruchart, JC | 1 |
| Staels, B | 1 |
| Duriez, P | 1 |
| Lacroix, D | 1 |
| Chew, GT | 1 |
| Watts, GF | 1 |
| Davis, TM | 1 |
| Stuckey, BG | 1 |
| Beilin, LJ | 1 |
| Thompson, PL | 1 |
| Burke, V | 1 |
| Currie, PJ | 1 |
| de Lorgeril, M | 1 |
| Salen, P | 1 |
| Bontemps, L | 1 |
| Belichard, P | 1 |
| Geyssant, A | 1 |
| Itti, R | 1 |
2 trials available for fenofibrate and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diabe | 2008 |
Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.
Topics: Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyspepsia; Exercise Test; F | 1999 |
6 other studies available for fenofibrate and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Fenofibrate reduces cardiac remodeling and improves cardiac function in a rat model of severe left ventricle volume overload.
Topics: Animals; Aortic Valve Insufficiency; Disease Models, Animal; Fatty Acids; Fenofibrate; Hypolipidemic | 2013 |
Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure.
Topics: Animals; Ceramides; Dietary Fats; Disease Models, Animal; Feeding Behavior; Fenofibrate; Heart Failu | 2006 |
Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats.
Topics: Actin Cytoskeleton; Animals; Calcium; Endotoxins; Fenofibrate; Hypolipidemic Agents; Lipopolysacchar | 2007 |
Sepsis-induced myocardial depression: where is the missing link?
Topics: Actin Cytoskeleton; Animals; Apoptosis; Calcium; Endotoxins; Energy Metabolism; Fenofibrate; Hypolip | 2007 |
Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity.
Topics: Animals; Dose-Response Relationship, Drug; Doxorubicin; Drug Combinations; Fenofibrate; Hypolipidemi | 2007 |
The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
Topics: Acyl-CoA Oxidase; Animals; Atrial Natriuretic Factor; Biomarkers; Cardiac Output, Low; Cardiomyopath | 2007 |